Pharma Major Cipla Reports Q1 FY27 Results; Net Profit Declines 39% YoY Despite Revenue Growth; Check Details
Join Us
Follow Us
Cipla reported a modest increase in revenue during Q1 FY27, while profitability declined on a high base, even as the company continued to strengthen its global pharmaceutical business.
✨ Key Takeaways
On Thursday, Indian equity benchmark indices traded lower, with the benchmark Nifty 50 index declining 141.85 points, or 0.59 per cent, to 23,854.40. Amid this muted sentiment, Cipla share price declined 1.20 per cent to Rs 1,398.10 after the company announced its financial results for the quarter ended June 30, 2026.
Cipla Q1 FY27 Results
Cipla reported revenue from operations of Rs 7,119.28 crore in Q1 FY27, registering a 2.33 per cent YoY increase from Rs 6,957.47 crore in the corresponding quarter last year. Total income stood at Rs 7,330.18 crore, compared with Rs 7,216.03 crore in Q1 FY26.
The company's profit before Tax (PBT) declined 38.87 per cent YoY to Rs 1,081.93 crore from Rs 1,769.93 crore in the year-ago period. Net profit attributable to the owners of the parent fell 39.19 per cent YoY to Rs 789.05 crore, compared with Rs 1,297.62 crore in Q1 FY26. Consolidated net profit stood at Rs 785.55 crore, down 39.18 per cent YoY from Rs 1,291.61 crore, while basic earnings per share (EPS) came in at Rs 9.77, compared with Rs 16.07 a year earlier.
On a sequential basis, revenue from operations increased from Rs 6,541.20 crore in Q4 FY26 to Rs 7,119.28 crore, while consolidated net profit improved from Rs 542.51 crore to Rs 785.55 crore.
Also Read - 1:1 Bonus Issue: This Low PE, High ROCE Textile Stock Approves Bonus Shares, Final Dividend & Entry Into Grey Fabric Business; Check If You Hold
Cipla Key Developments
During the quarter, the company allotted 62,685 equity shares under its employee stock option schemes, increasing its paid-up equity share capital to Rs 161.57 crore. The company also stated that the proposed Scheme of Amalgamation of Inzpera Healthsciences Limited, its wholly owned subsidiary, with Cipla Limited is awaiting approval from the National Company Law Tribunal (NCLT), Mumbai.
Cipla further reiterated that it expects a favourable legal outcome in the long-pending NPPA overcharging litigation and, based on legal advice, has not made any additional provision against the disputed demand notices.
About Cipla
Founded in 1935, Cipla Ltd is one of India's leading global pharmaceutical companies engaged in the development, manufacturing and marketing of a wide range of pharmaceutical products. The company has a diversified portfolio spanning respiratory, anti-infective, cardiovascular, oncology, central nervous system, urology and other therapeutic segments, with operations across India and international markets.
Cipla operates through an extensive global network of manufacturing facilities, subsidiaries and distribution channels across North America, Europe, Africa, Asia-Pacific and emerging markets. The company continues to focus on innovation, affordability and expanding access to high-quality medicines while strengthening its global presence through strategic investments and product launches.
Add DSIJ as your preferred news source on G o o g l e
Add NowShare your thoughts on Cipla's Q1 FY27 performance in the comments below.
Disclaimer: The article is for informational purposes only and not investment advice.